Price
No data yet.
Social Signal Score
Analyst Ratings
7 analystsRevenue
$172.78MAnalyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Charles Bachtell
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Employees
- 2,900
- Beta
- 1.72
- Country
- US
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- -0.77
Financials
Revenue
$172.78M+7744.7%Net Income
$-12.44MEBITDA
$10.35MFree Cash Flow
$20.53MEPS (diluted)
$-0.03Shares Outstanding (diluted)
372.90M+1071303.2%Operating Expenses
$68.82MCash & Debt
$41.17MReturn of Capital
$0.00Revenue by Segment (annual)
$655.85MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $667.33M | $-137.78M | $-0.39 |
| 2024 | $724.34M | $-74.44M | $-0.22 |
| 2023 | $770.88M | $-175.52M | $-0.54 |
| 2022 | $842.68M | $-212.05M | $-0.71 |
| 2021 | $821.68M | $-319.60M | $-1.22 |
| 2020 | $476.25M | $-102.16M | $-0.49 |
| 2019 | $128.53M | $-43.20M | $-0.37 |
| 2018 | $43.25M | $-1.92M | $-0.03 |
| 2017 | $10.31M | $-85.8K | $-2.63 |
| 2016 | $0.00 | $-108.6K | $-3.10 |
| 2015 | $0.00 | $47.4K | $1.16 |
| 2014 | $0.00 | $-117.4K | $-3.38 |
| 2013 | $0.00 | $-202.7K | $-5.82 |
| 2012 | $0.00 | $-361.4K | $-10.38 |
Valuation
CRLBFhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
150+400.00%Social Signal Score
Mentions (9)
- Newsseekingalpha.com·16d ago·Positive
Cresco Labs Inc. (CRLBF) Q3 2026 Earnings Call Transcript Cresco Labs Inc. (CRLBF) Q3 2026 Earnings Call Transcript
View source ↗ - Newszacks.com·16d ago·Negative
Cresco Labs Inc. (CRLBF) Reports Q3 Loss, Misses Revenue Estimates Cresco Labs Inc. (CRLBF) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.02. This compares to a loss of $0.05 per share a year ago.
View source ↗ - Newsbusinesswire.com·16d ago·Neutral
Cresco Labs Reports Third Quarter 2026 Financial Results CHICAGO--(BUSINESS WIRE)--Cresco Labs Reports Third Quarter 2026 Financial Results.
View source ↗ - Newsbusinesswire.com·17d ago·Neutral
Cresco Labs Advances Innovation Pipeline with High Supply SLIPS and Wonder THC Drink Mixes CHICAGO--(BUSINESS WIRE)--Cresco Labs Inc. (CSE: CL) (OTCQX: CRLBF) (“Cresco Labs” or the “Company”), today announced two new additions to its portfolio of leading cannabis brands: High Supply SLIPS—fast-acting oral THC pouches—and Wonder THC Drink Mixes—single-serving beverage packets. The launches reflect the Company's focus on identifying unmet consumer needs, creating new consumer occasions, and develo…
View source ↗ - Newsseekingalpha.com·23d ago·Neutral
Cresco Labs Inc. (CRLBF) Shareholder/Analyst Call Prepared Remarks Transcript Cresco Labs Inc. (CRLBF) Shareholder/Analyst Call Prepared Remarks Transcript
View source ↗ - Newsbusinesswire.com·38d ago·Neutral
Cresco Labs to Report Third Quarter 2026 Financial Results on November 6, 2026 CHICAGO--(BUSINESS WIRE)--Cresco Labs Inc. (CSE:CL) (OTCQX:CRLBF) (FSE: 6CQ) (“Cresco” or the “Company”), the industry leader in branded cannabis products with a portfolio of America's most popular brands and the operator of Sunnyside dispensaries, today announced that it will report its financial results for the third quarter ended September 30, 2026, before the market opens on Friday, November 6, 2026. The Company w…
View source ↗ - Newsbusinesswire.com·66d ago·Neutral
Cresco Labs Appoints Edward Tilly to Board of Directors CHICAGO--(BUSINESS WIRE)--Cresco Labs Inc. (CSE: CL) (OTCQX: CRLBF) (FSE: 6CQ) (“Cresco Labs” or the “Company”), the industry leader in branded cannabis products with a portfolio of America's most popular brands and the operator of Sunnyside dispensaries, today announced the appointment of Edward Tilly to its Board of Directors, effective September 18, 2026. Mr. Tilly will serve as an independent director and join the Audit Committee, bring…
View source ↗ - Newsbusinesswire.com·81d ago·Negative
…co Labs Acquires Nine Pennsylvania Dispensaries in Accretive Transaction to Strengthen Market Leadership CHICAGO--(BUSINESS WIRE)--Cresco Labs Inc. (CSE: CL) (OTCQX: CRLBF) (FSE: 6CQ) (“Cresco Labs” or the “Company”) today announced the closing of its acquisition of 100% of the outstanding equity interests in PharmaCann Penn, LLC (“PharmaCann”) for an aggregate consideration of US$50 million (the “Transaction”). The Transaction consists of nine operational retail medical marijuana dispensaries i…
View source ↗ - Newsmarijuanastocks.com·102d ago·Neutral
3 Marijuana Stocks For Investors To Consider What will help marijuana stock investors trade more, even in the midst of laws changing in the USA? It is no secret that nothing has moved pot stocks more than news of global reform or regulatory matters. For the US, what happens at the federal level has moved the needle the most, with the recent passing of legislation to reclassify cannabis to Schedule 3.
View source ↗
Earnings
Thu, Mar 4(in 3 months)
Consensus estimate $-0.03 per share
Typical surprise -33.3% (median, so one quarter with a near-zero estimate can't distort it)
- Fri, Nov 6$-0.03 vs $-0.02miss
- Thu, Aug 6$0.04 vs $-0.02beat
- Fri, May 8$-0.04 vs $-0.03miss
- Thu, Mar 5$-0.24 vs $-0.01miss
- Wed, Nov 5$-0.05 vs $-0.03miss
- Thu, Aug 7$-0.05 vs $-0.04miss
Estimates and results for CRLBF via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Congress trades
No disclosed congressional trades in CRLBF.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
